A groundbreaking Cochrane systematic review has revealed that planned early delivery for pregnant women grappling with hypertensive disorders can significantly mitigate maternal health complications and substantially reduce stillbirth risks without leading to increased cesarean section rates. This revelation carries immense implications for clinical guidelines and decision-making in obstetrics, especially for conditions such as pre-eclampsia, gestational hypertension, and chronic hypertension — which collectively stand as the second leading cause of maternal mortality worldwide.
Hypertensive disorders during pregnancy encompass a complex array of conditions, with pre-eclampsia characterized by high blood pressure and organ damage, typically the kidneys and liver. The pathophysiological cornerstone of pre-eclampsia lies in placental dysfunction, making early delivery the only definitive therapeutic intervention, as the disease process is intrinsically linked to the presence of the placenta. This placenta-dependent aspect means that symptoms and complications generally resolve only after the delivery of the placenta, necessitating precise timing in birth planning to optimize both maternal and neonatal outcomes.
Led by researchers at King’s College London, the review synthesized data obtained from six randomized controlled trials that collectively included 3,491 women affected by hypertensive disorders. These trials spanned a broad geographic scope, incorporating diverse healthcare environments in countries such as the Netherlands, the United Kingdom, the United States, India, and Zambia. The trials compared the outcomes of planned early birth — performed from 34 weeks’ gestation onwards — against a strategy of expectant management, where delivery is delayed in favor of close surveillance aiming to prolong pregnancy to a later gestational age.
The comprehensive analysis produced high-certainty evidence indicating that planned early delivery nearly halved the incidence of severe maternal complications, compared to watchful waiting. Severe complications in this context encompass life-threatening conditions such as eclampsia, stroke, and multi-organ failure. This reduction demonstrates a crucial advantage in maternal safety, underscoring the role of timely birth intervention to prevent catastrophic maternal morbidity and mortality associated with hypertensive diseases during pregnancy.
Intriguingly, while stillbirth remains a significant threat in pregnancies complicated by hypertension, the review suggests that planned early birth might decrease stillbirth risk by approximately 75%. However, this finding is supported by moderate-certainty evidence and is primarily driven by data from one trial conducted in regions with higher baseline stillbirth rates (India and Zambia). In contrast, trials in higher-income countries reported no stillbirths, suggesting that the benefits of early delivery for fetal outcomes may depend on available healthcare infrastructure and population risk profiles.
Another reassuring facet of these findings is the likely absence of increased neonatal unit admissions following early planned delivery. This counters prevailing concerns that inducing birth preterm might escalate the need for intensive neonatal care. Although this conclusion relies on moderate-certainty evidence, it affirms that delivery timing decisions can optimize maternal safety without compromising neonatal wellbeing through excessive prematurity-related complications.
A compelling feature of the evidence base is the consistency of benefits across both resource-rich and resource-limited settings. The maternal health advantages of early birth held true irrespective of whether women received intensive monitoring or less resourced care, emphasizing the broad applicability of early delivery as a clinical strategy. This cross-contextual validity strengthens the recommendation for planned early delivery in hypertensive pregnancies globally.
Prof Catherine Cluver, senior author and investigator at Stellenbosch University and Tygerberg Hospital, highlighted that the review offers clearer clinical guidance on managing complicated pregnancies due to hypertension. Specifically, planned delivery is advocated from as early as 34 weeks but no later than 37 weeks gestation, particularly for women diagnosed with pre-eclampsia, marking a shift towards more proactive obstetric care in this high-risk group.
Lead author Dr Alice Beardmore-Gray, an obstetrician at King’s College London, emphasized the enduring clinical challenge of determining optimal delivery timing in hypertensive pregnancies. The review’s findings demystify this dilemma by demonstrating that delaying birth to prolong pregnancy does not necessarily afford maternal or fetal benefits and, in many cases, risks precipitating emergency deliveries under deteriorated conditions.
Supporting this perspective, data from two included trials revealed that over half the women initially managed expectantly required emergency delivery before 37 weeks anyway—typically within just days of when planned early birth would have occurred. These emergency deliveries correlated with higher complication rates for both mothers and infants, underscoring that postponement without clear clinical justification can exacerbate risks rather than mitigate them.
Critically, the review found high-certainty evidence that planned early delivery does not increase the risk of cesarean section, a finding that directly addresses a common concern among expectant mothers and clinicians alike. The fear that induction or early planned birth might lead to more surgical interventions is therefore not substantiated, which facilitates more transparent and informed counseling regarding birth timing decisions in hypertensive pregnancies.
The authors advocate that clinicians carefully incorporate individual women’s preferences and the severity of hypertensive disease manifestations when deciding the timing of delivery. Current international guidelines are reinforced by these findings, recommending planned early birth by 37 weeks for all women with pre-eclampsia. For those with less severe gestational or chronic hypertension, continued careful monitoring may allow delay until 39 weeks, balancing risks and benefits.
Despite the encouraging findings, the review calls for further research into the longer-term outcomes of infants born late preterm, especially concerning neurodevelopmental and respiratory health, as well as the protracted cardiovascular sequelae for mothers who experience hypertensive disorders during pregnancy. Such data will be invaluable to comprehensively assess the extended impact of early delivery strategies and inform future recommendations.
This systematic review marks a pivotal advancement in managing hypertensive pregnancies, offering robust evidence to support planned early delivery as a strategy that improves maternal safety and potentially fetal outcomes without escalating surgical birth rates. As hypertensive disorders continue to challenge perinatal care globally, especially in low-resource settings, these insights bear critical clinical and public health significance.
Subject of Research: People
Article Title: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks’ gestation to term
News Publication Date: 20-May-2026
Web References: http://dx.doi.org/10.1002/14651858.CD009273.pub3
References: Cochrane Database of Systematic Reviews
Image Credits: None provided
Keywords: Hypertension, Pre-eclampsia, Gestational hypertension, Pregnancy complications, Planned early delivery, Maternal health, Stillbirth, Cesarean section, Late preterm birth, Obstetrics, Clinical trials, Maternal mortality
